Cargando…

Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer

Aberrant DNA methylation observed in cancer can provide survival benefits to cells by silencing genes essential for anti-tumor activity. DNA-demethylating agents such as Decitabine (DAC)/Azacitidine (AZA) activate otherwise silenced tumor suppressor genes, alter immune response and epigenetically re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramakrishnan, Swathi, Hu, Qiang, Krishnan, Nithya, Wang, Dan, Smit, Evelyn, Granger, Victoria, Rak, Monika, Attwood, Kristopher, Johnson, Candace, Morrison, Carl, Pili, Roberto, Chatta, Gurkamal, Guru, Khurshid, Gueron, Geraldine, McNally, Lacey, Wang, Jianmin, Woloszynska-Read, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870579/ https://www.ncbi.nlm.nih.gov/pubmed/29242529 http://dx.doi.org/10.1038/s41419-017-0024-5

Ejemplares similares

Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer
por: Ramakrishnan, Swathi, et al.
Publicado: (2019)

Serum Androgen Metabolites Correlate with Clinical Variables in African and European American Men with Localized, Therapy Naïve Prostate Cancer
por: Ramakrishnan, Swathi, et al.
Publicado: (2023)

STAG2 Expression is Associated with Adverse Survival Outcomes and Regulates Cell Phenotype in Muscle-invasive Bladder Cancer
por: Athans, Sarah R., et al.
Publicado: (2022)

NFκB-Activated COX2/PGE(2)/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues
por: Ibrahim, Omar M., et al.
Publicado: (2021)

DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire
por: Nie, Jing, et al.
Publicado: (2016)

Vitamin D(3) enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk
por: Bunch, Brittany L., et al.
Publicado: (2019)

Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines
por: Hagemann, Sabine, et al.
Publicado: (2011)

Role of tumor microenvironment in the efficacy of BCG therapy
por: Ibrahim, Omar M, et al.
Publicado: (2020)

Synergistic Cytotoxic Effect of L-Asparaginase Combined with Decitabine as a Demethylating Agent in Pediatric T-ALL, with Specific Epigenetic Signature
por: Serravalle, Salvatore, et al.
Publicado: (2016)

Decitabine and Cisplatin are Synergistic to Exert Anti-Tumor Effect on Gastric Cancer via Inducing Sox2 DNA Demethylation
por: Zhu, Zhipeng, et al.
Publicado: (2021)

T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
por: Yamauchi, Takayoshi, et al.
Publicado: (2021)

Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptotic genes as targets for demethylation
por: Al-Romaih, Khaldoun, et al.
Publicado: (2007)

Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway
por: Jin, Yulong, et al.
Publicado: (2019)

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
por: Dolan, Melissa, et al.
Publicado: (2019)

Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemness
por: Liu, Xiaozhuo, et al.
Publicado: (2022)

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage
por: Ciamporcero, Eric, et al.
Publicado: (2015)

Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways
por: Tomar, Tushar, et al.
Publicado: (2016)

Association between Functional Brain Network Metrics and Surgeon Performance and Distraction in the Operating Room
por: Shafiei, Somayeh B., et al.
Publicado: (2021)

Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity
por: Briot, Thomas, et al.
Publicado: (2019)

Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target
por: Li, Kongfei, et al.
Publicado: (2014)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

Efficacy of decitabine-loaded gelatinases-stimuli nanoparticles in overcoming cancer drug resistance is mediated via its enhanced demethylating activity to transcription factor AP-2 epsilon
por: Hong, Yi-Dong, et al.
Publicado: (2017)

Association among plasma 1,25(OH)(2)D, ratio of 1,25(OH)(2)D to 25(OH)D, and prostate cancer aggressiveness
por: Ramakrishnan, Swathi, et al.
Publicado: (2019)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Loss of MAGEC3 Expression Is Associated with Prognosis in Advanced Ovarian Cancers
por: Ellegate, James, et al.
Publicado: (2022)

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts
por: Wei, Lei, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers
por: Soni, Amy, et al.
Publicado: (2015)

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
por: Qin, Taichun, et al.
Publicado: (2011)

Correction to: Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

Structure and function of dioxygenases in histone demethylation and DNA/RNA demethylation
por: Dong, Cheng, et al.
Publicado: (2014)

Mixed-phenotype acute leukemia treated with decitabine
por: Lee, Ji-Young, et al.
Publicado: (2016)

Epigenetic synergy between decitabine and platinum derivatives
por: Qin, Taichun, et al.
Publicado: (2015)

Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
por: Jing, Yu, et al.
Publicado: (2015)

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy
por: Agasthi, Pradyumna, et al.
Publicado: (2018)

Expression of decitabine-targeted oncogenes in meningiomas in vivo
por: Canisius, Julian, et al.
Publicado: (2022)

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells
por: Gillardin, Pierre-Samuel, et al.
Publicado: (2017)

Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine
por: HOSOKAWA, MIKA, et al.
Publicado: (2015)

A randomized phase II study of pazopanib in hormone sensitive prostate cancer: a University of Chicago Phase II Consortium/ Department of Defense Prostate Cancer Clinical Trials Consortium study
por: Ward, James E., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_s0ki6cccfu3ebeplhf560m3qvt